高级检索
当前位置: 首页 > 详情页

Enhanced mitochondrial pyruvate transport elicits a robust ROS production to sensitize the antitumor efficacy of interferon-γ in colon cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Hubei Univ Med, Renmin Hosp, Dept Oncol, 39 Chaoyang Middle Rd, Shiyan 442000, Hubei, Peoples R China [2]Huazhong Univ Sci & Technol, Dept Rehabil Med, Tongji Hosp, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China [3]Huazhong Univ Sci & Technol, Ctr Canc, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei, Peoples R China [4]Hubei Univ Med, Lab Chinese Herbal Pharmacol, Hubei Key Lab Wudang Local Chinese Med Res, Oncol Ctr,Rennin Hosp, Shiyan 442000, Hubei, Peoples R China [5]Huazhong Univ Sci & Technol, Dept Biochem & Mol Biol, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China [6]Danjiangkou First Hosp, Dept Oncol, Danjiangkou 442700, Hubei, Peoples R China [7]Hubei Univ Med, Dept Med Imaging Ctr, Renmin Hosp, Shiyan 442000, Hubei, Peoples R China [8]Hubei Univ Med, Inst Canc Res, Renmin Hosp, Shiyan 442000, Hubei, Peoples R China
出处:
ISSN:

关键词: Interferon-gamma Mitochondrial pyruvate carriers Redox Colon cancer Glycolysis

摘要:
Metabolic reprogramming is a feature of cancer cells and crucial for tumor growth and metastasis. Interferon-gamma (IFN gamma) is a cytokine that plays a pivotal role in host antitumor immunity. However, little is known about the roles of metabolic reprogramming in immune responses. Here, we show that colon cancer cells reprogram metabolism to coordinate proper cellular responses to IFN gamma by downregulating mitochondrial pyruvate carrier (MPC)1 and 2 via STAT3 signaling. Forced overexpression of MPC promote the production of reactive oxygen species and enhance the apoptosis induced by IFN gamma in colon cancer cells. Moreover, inhibiting STAT3 sensitize the antitumor efficacy of IFN-gamma against colon cancer cells. Our findings present a previously unrecognized mechanism that colon cancer manipulate to resist IFN gamma mediated antitumor immunity that have implications for targeting a unique aspect of this disease.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类 | 2 区 生物
小类 | 2 区 生化与分子生物学
最新[2025]版:
大类 | 1 区 生物学
小类 | 1 区 生化与分子生物学
JCR分区:
出版当年[2017]版:
Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY
最新[2023]版:
Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2017版] 出版当年五年平均 出版前一年[2016版] 出版后一年[2018版]

第一作者:
第一作者单位: [1]Hubei Univ Med, Renmin Hosp, Dept Oncol, 39 Chaoyang Middle Rd, Shiyan 442000, Hubei, Peoples R China
通讯作者:
通讯机构: [1]Hubei Univ Med, Renmin Hosp, Dept Oncol, 39 Chaoyang Middle Rd, Shiyan 442000, Hubei, Peoples R China [8]Hubei Univ Med, Inst Canc Res, Renmin Hosp, Shiyan 442000, Hubei, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:434 今日访问量:0 总访问量:419 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)